← Catalyst calendarMSLE biotech catalysts & pipeline
SATELLOS BIOSCIENCE INC · Data as of 2026-09-08
Upcoming catalysts
SAT-3247 — IND submission
H2 2026
Satellos plans to submit an Investigational New Drug application and begin clinical research to investigate the use of SAT-3247 in individuals living with facioscapulohumeral muscular dystrophy (FSHD) in the second half of 2026 and has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development.
Source filingSAT-3247 — NDA/BLA submission
H2 2026
our anticipated filing of regulatory documents to initiate a Phase 2 clinical trial in FSHD (as defined hereinin the United States and Canada in the second half of 2026;
Source filingSAT-3247 — Topline data
Q4 2026
Enrollment anticipated to complete in the third quarter of 2026 with top-line data expected in the fourth quarter of 2026
Source filingExplore the free biotech catalyst calendar